Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Charles Duncan, Piper Jaffray & Co. (4/21/15)
"Inovio Pharmaceuticals Inc. announced this morning that it has started the Phase 2 study of its innovative hepatitis B virus (HBV) candidate. The SynCon vaccine INO-1800 is designed to treat HBV and it will be evaluated with and without INO-9112 for interleukin-12 expression. . .this news enhances our conviction regarding the strength of the company's partnership with Roche Holding AG for this program."

Jason Kolbert, Maxim Group (4/21/15)
"Inovio Pharmaceuticals Inc.'s INO-1800, a DNA-based vaccine against hepatitis B virus (HBV) and partnered to Roche Holding AG, initiated a Phase 1 trial in patients with chronic HBV infection. . .though this is primarily a safety study, we should get a readout of the immune response (antibodies and T-cells), which should help advance INO-1800 into further trials."

Jason Kolbert, Maxim Group (4/9/15)
"Data from Inovio Pharmaceuticals Inc.'s vaccination study shows the company's continued expansion in the HPV-related disease space and continued progress in oncology. VGX-3100, which is heading towards a Phase 3 registration study (early 2016) in precancerous cervical disease caused by HPV, showed in a Phase 2 study that HPV T-cell responses could induce histological regression of disease and clear virus."

Charles Duncan, Piper Jaffray & Co. (4/9/15)
"Inovio Pharmaceuticals Inc. reported that it will present the first immunological data on its SynCon vaccine platform used to treat cancer patients at the World Vaccine Congress. Impressively, robust T-cell responses were seen in 3 of the 4 examined head and neck patients. While we have yet to see the data, it supports our thesis that the company's SynCon is a leading immunooncology DNA-based therapeutic vaccine platform and supports additional studies in head and neck cancer, cervical cancer and dysplasia, all of which are often HPV driven."

Yi Chen, H.C. Wainwright & Co. (4/9/15)
"Inovio Pharmaceuticals Inc. announced yesterday that the company has been selected by the Defense Advanced Research Projects Agency (DARPA) to lead a consortium and a treatment and prevention program against Ebola. The DARPA funding period is over two years and covers a base award of $21M and an option award of $24M. . .we view this grant as a validation of Inovio's DNA-based immunotherapy technology platform."

Charles Duncan, Piper Jaffray & Co. (4/8/15)
"Inovio Pharmaceuticals Inc. announced another grant this morning that provides additional external validation of the platform, as well as nondilutive funding with which to advance the pipeline. This one is from the Defense Advanced Research Projects Agency for Ebola and is valued up to $45M over two years. . .we continue to view the company's DNA-based platform for immunotherapy as class leading and look forward to a productive 12–18 months."

Management Q&A: View From the Top
J. Joseph Kim
Inovio Pharma- ceuticals Inc. (INO:NYSE.MKT) is in the forefront of developing DNA vaccines, inserting engineered genes into cellular machinery to synthesize proteins that, in turn, generate antibodies that fight disease. If pivotal studies read out favorably, DNA immunization could prove a true game changer in healthcare. In this interview with The Life Sciences Report, Inovio President and CEO J. Joseph Kim discusses his company's platform technology, which addresses both therapeutic and preventive methods of fighting disease.
read more >

More Comments

Experts Commenting on This Company

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Inovio Pharmaceuticals Inc. Content